![Amazon.com: Adventures of an IT Leader: 8601400713747: Austin, Robert D., Nolan, Richard L., O'Donnell, Shannon: Books Amazon.com: Adventures of an IT Leader: 8601400713747: Austin, Robert D., Nolan, Richard L., O'Donnell, Shannon: Books](https://m.media-amazon.com/images/W/IMAGERENDERING_521856-T1/images/I/41KCcsejVnL._AC_UF350,350_QL80_.jpg)
Amazon.com: Adventures of an IT Leader: 8601400713747: Austin, Robert D., Nolan, Richard L., O'Donnell, Shannon: Books
![Cancers | Free Full-Text | Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop Cancers | Free Full-Text | Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop](https://www.mdpi.com/cancers/cancers-13-04135/article_deploy/html/images/cancers-13-04135-g001.png)
Cancers | Free Full-Text | Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop
![Cureus | Primary Undifferentiated Pleomorphic Sarcoma of the Biceps Femoris Muscle Complicated by Hemorrhage: An Underrecognized Entity | Article Cureus | Primary Undifferentiated Pleomorphic Sarcoma of the Biceps Femoris Muscle Complicated by Hemorrhage: An Underrecognized Entity | Article](https://assets.cureus.com/uploads/figure/file/240110/lightbox_2a47f240e63711eba1834b83143cf1c0-Figure-1a.png)
Cureus | Primary Undifferentiated Pleomorphic Sarcoma of the Biceps Femoris Muscle Complicated by Hemorrhage: An Underrecognized Entity | Article
![Cancers | Free Full-Text | Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity Cancers | Free Full-Text | Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity](https://pub.mdpi-res.com/cancers/cancers-13-04867/article_deploy/html/images/cancers-13-04867-g001.png?1632984951)
Cancers | Free Full-Text | Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
![Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients | Blood Cancer Journal Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-023-00794-x/MediaObjects/41408_2023_794_Fig1_HTML.png)
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients | Blood Cancer Journal
![Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma | Leukemia Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2017.58/MediaObjects/41375_2017_Article_BFleu201758_Fig1_HTML.jpg)